肝癌患者经系统治疗后甲胎蛋白变化对预后的影响

目的:探讨肝癌患者经系统治疗后甲胎蛋白(AFP)变化对患者预后的影响。方法:对53例肝癌患者于入院后和系统治疗后分别于不同时间点测定血清AFP值后,将入院时AFP值作为基线,以变化50%作为标准分组,并进行无疾病进展生存时间(PFS)和总生存时间(OS)分析。结果:9例患者血清AFP值下降超过50%(A组),28例患者AFP值升高超过50%(B组),而AFP值变化小于50%(C组)的为16例。和C组相比,A组患者PFS明显延长(P<0.05),B组PFS明显缩短(P<0.05)。B组OS短于C组(P<0.01),而A组和C组间OS无明显差别(P>0.05)。结论:肝癌系统治疗前后的AFP值变化可作为临床上预后判断的标志之一。

Prognostic Influence of Changes of Alpha-Fetoprotein in Patients receiving Systemic Therapy with Hepatocellular Carcinoma

Objective: To explore the prognostic influence of the changes of alpha-fetoprotein in patients receiving systemic therapy with hepatocellular carcinoma.Methods: Serum AFP was collected at baseline and at different time points after admission receiving sys-temic therapy in 53 patients with hepatocellular carcinoma.Patients were separated into different groups based on a 50% change in serum AFP from baseline.Overall survival(OS),progression-free survival(PFS) were compared between groups.Results: Nine patients experi-enced a >50% AFP decline(Group A),28 patients had a>50%AFP increase(Group B),and 16 patients had a <50% change in serum AFP in either direction(Group C).Compared with Group C,Group A had a longer PFS time(P<0.05),whereas Group B had a shorter PFS time(P<0.05).Group B had a shorter OS time than Group C(P<0.01),whereas Group A was not associated with a significant differ-ence in OS(P>0.05).Conclusion: Serum AFP change may serve as a useful marker for clinical outcome and prognostic influence in pa-tients with hepatocellular carcinoma receiving systemic therapy.